Teva gets mixed news on patent disputes; fails over Gemzar with Lilly, prevails in fight with Watson: Sanofi in more Eloxatin settlements
A federal judge in the USA has ruled that Teva Pharmaceuticals USA's Abbreviated New Drug Applications for the cancer drug Gemzar (gemcitabine) infringe a patent of US drug major Eli Lilly, enjoining the Israeli-owned generics giant from introducing its own version of the cancer drug until at least November.
Judge Sarah Evans Barker of the US District Court for the Southern District of Indiana issued the ruling last week, preventing Teva from manufacturing its generic version until Lilly's patent expires on November 15.
However, the Court denied Lilly's request for an injunction on a method of use patent, expiring May 7, 2013, on the grounds that the Eastern District of Michigan had previously found that patent invalid. Lilly has appealed that decision and oral argument is scheduled for May 7, 2010.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze